Drug Profile
Ethonafide - OSI Pharmaceuticals
Alternative Names: AMP-53Latest Information Update: 22 Sep 2017
Price :
$50
*
At a glance
- Originator OSI Pharmaceuticals
- Class Anthracenes; Antineoplastics; Isoquinolines; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Sep 2017 Chemical structure information added
- 31 Dec 2003 Development discontinued for Cancer before 2004
- 20 Oct 1995 Investigation in Cancer in USA (IV)